Literature DB >> 26521277

Eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): where are we now?

Matthieu Groh1, Christian Pagnoux2, Loïc Guillevin3.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 26521277     DOI: 10.1183/13993003.00963-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  5 in total

1.  Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): single-center experience in 18 cases.

Authors:  Zeynep Celebi Sozener; Begum Gorgulu; Dilsad Mungan; Betul Ayse Sin; Zeynep Misirligil; Omur Aydin; Sevim Bavbek
Journal:  World Allergy Organ J       Date:  2018-12-03       Impact factor: 4.084

2.  Severe anaphylactic shock after anesthesia induction: An unusual initial manifestation of Churg-Strauss syndrome.

Authors:  Aikaterini Melemeni; Aliki Tympa Grigoriadou; Stavroula Karachanidi; Athanasia Tsaroucha
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

3.  Severe Adult Asthmas: Integrating Clinical Features, Biology, and Therapeutics to Improve Outcomes.

Authors:  Sally E Wenzel
Journal:  Am J Respir Crit Care Med       Date:  2021-04-01       Impact factor: 21.405

4.  Short-term use of "ECMELLA" in the context of fulminant eosinophilic myocarditis with cardiogenic shock.

Authors:  Mintje Bohné; Da-Un Chung; Eike Tigges; Hendrick van der Schalk; Daniela Waddell; Niklas Schenker; Stephan Willems; Karin Klingel; Dietmar Kivelitz; Edda Bahlmann
Journal:  BMC Cardiovasc Disord       Date:  2020-12-10       Impact factor: 2.298

5.  Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series.

Authors:  Aikaterini Detoraki; Eugenio Tremante; Remo Poto; Emanuela Morelli; Giuseppe Quaremba; Francescopaolo Granata; Antonio Romano; Ilaria Mormile; Francesca Wanda Rossi; Amato de Paulis; Giuseppe Spadaro
Journal:  Respir Res       Date:  2021-06-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.